<DOC>
	<DOCNO>NCT02360696</DOCNO>
	<brief_summary>Duodenal eosinophilia associate dyspepsia adult investigator previously describe find duodenal mucosal eosinophilia 71-79 % child undergoing diagnostic endoscopy . Previous study child show positive response montelukast approximately 50 % find complete relief 20-30 percent show response . There number factor potential contribute observe variability response montelukast . These include variability : 1. systemic drug exposure ( drug absorption , biotransformation and/or elimination ) 2. regulation leukotriene biosynthesis 3. cysteinyl leukotriene receptor downstream mediator 4. patient disease phenotype ( e.g . Functional Gastrointestinal Disorder ( FGID ) disease classification , psychologic profile ) In study , investigator propose utilize biopsy specimen stratify drug response identify candidate gene expression module validate prospective study design . The overall goal program develop signature montelukast response apply eosinophilic gastroenteritis , generally diseases , asthma , drug widely use variable success .</brief_summary>
	<brief_title>Functional Dyspepsia ( FD ) - Clinical Response Montelukast Children</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Ages 8 17 year , inclusive Abdominal pain least 8 week duration fulfil symptom base criterion functional dyspepsia Scheduled endoscopy follow failure respond acidreduction therapy Evidence write parental permission ( consent ) subject assent Previous treatment montelukast Treatment corticosteroids oral cromolyn sodium four week prior enrollment Prior history clinical signs/symptoms chronic disease require regular medical care ( e.g. , diabetes mellitus , juvenile idiopathic arthritis , cystic fibrosis cancer ) Exposure within past two week drug natural product induce CYP2C8/9 CYP3A4 , include amprenavir , carbamazepine , lopinavir/ritonavir , nafcillin , nevirapine , oxcarbazepine , phenobarbital , phenytoin , rifampin , St. John 's Wort , inhibit CYP2C8/9 CYP3A4 , ciprofloxacin , clarithromycin , erythromycin , fluconazole , fluvoxamine , grapefruit juice , paroxetine , sertraline , sulfamethoxazole , trimethoprim A Body Mass Index 30 great NonEnglish speaking Those patient turn 18 duration study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Duodenal Eosinophilia</keyword>
	<keyword>Functional Dyspepsia</keyword>
	<keyword>Mucosal Eosinophilia</keyword>
</DOC>